By Jeff Overley (January 30, 2014, 3:41 PM EST) -- Drugmakers are scrambling to limit the scope of the U.S. Supreme Court's landmark antitrust decision in Federal Trade Commission v. Actavis, arguing with mixed results that the ruling only requires extra scrutiny of deals to delay generic competition if money changed hands.
A ruling out of New Jersey federal court last week represented an early victory for the pharmaceutical industry, but judges elsewhere have hinted that they may take a broader view of last year's Actavis decision. Experts see extensive litigation ahead, with the outcomes dramatically shaping the structure of settlements between brand-name and generic-drug makers.
"This is going to be...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!